New methods for finding common insertion sites and co-occurring common insertion sites in transposon- and virus-based genetic screens

Insertional mutagenesis screens in mice are used to identify individual genes that drive tumor formation. In these screens, candidate cancer genes are identified if their genomic location is proximal to a common insertion site (CIS) defined by high rates of transposon or retroviral insertions in a given genomic window. In this article, we describe a new method for defining CISs based on a Poisson distribution, the Poisson Regression Insertion Model, and show that this new method is an improvement over previously described methods. We also describe a modification of the method that can identify pairs and higher orders of co-occurring common insertion sites. We apply these methods to two data sets, one generated in a transposon-based screen for gastrointestinal tract cancer genes and another based on the set of retroviral insertions in the Retroviral Tagged Cancer Gene Database. We show that the new methods identify more relevant candidate genes and candidate gene pairs than found using previous methods. Identification of the biologically relevant set of mutations that occur in a single cell and cause tumor progression will aid in the rational design of single and combinatorial therapies in the upcoming age of personalized cancer therapy.

[1]  T. Scheetz,et al.  A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. , 2009, Cancer research.

[2]  Andrew I. Su,et al.  The Gene Wiki: community intelligence applied to human gene annotation , 2009, Nucleic Acids Res..

[3]  T. Suda,et al.  Craniofacial malformation in R-spondin2 knockout mice. , 2009, Biochemical and biophysical research communications.

[4]  Y. Asmann,et al.  A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer , 2009, Science.

[5]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[6]  Derek Y. Chiang,et al.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma , 2009, Nature Biotechnology.

[7]  R. Wang,et al.  Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model , 2008, BMC Cancer.

[8]  T. Hudson,et al.  Germline EPHB2 Receptor Variants in Familial Colorectal Cancer , 2008, PloS one.

[9]  J. Whitsett,et al.  R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis , 2008, Development.

[10]  T. Sugiura,et al.  Protein phosphatase 1H, overexpressed in colon adenocarcinoma, is associated with CSE1L , 2008, Cancer biology & therapy.

[11]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[12]  Andreas Prlic,et al.  Ensembl 2008 , 2007, Nucleic Acids Res..

[13]  W. Funk,et al.  Mouse R-spondin2 is required for apical ectodermal ridge maintenance in the hindlimb. , 2007, Developmental biology.

[14]  S. Rha,et al.  Whole genome analysis for liver metastasis gene signatures in colorectal cancer , 2007, International journal of cancer.

[15]  J. Fléjou,et al.  Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer , 2007, International journal of cancer.

[16]  C. Prives,et al.  hCAS/CSE1L Associates with Chromatin and Regulates Expression of Select p53 Target Genes , 2007, Cell.

[17]  Marcel J. T. Reinders,et al.  Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes , 2007, ISMB/ECCB.

[18]  J. Kleibeuker,et al.  Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  Marcel J. T. Reinders,et al.  Detecting Statistically Significant Common Insertion Sites in Retroviral Insertional Mutagenesis Screens , 2006, PLoS Comput. Biol..

[20]  J. A. Ferreira,et al.  On the Benjamini-Hochberg method , 2006, math/0611265.

[21]  A. Berns,et al.  Retroviral insertional mutagenesis: past, present and future , 2005, Oncogene.

[22]  Takeshi Oshima,et al.  Mitogenic Influence of Human R-Spondin1 on the Intestinal Epithelium , 2005, Science.

[23]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[24]  D. Largaespada,et al.  Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system , 2005, Nature.

[25]  Corey M. Carlson,et al.  Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse , 2005, Nature.

[26]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[27]  M. Bertagnolli,et al.  Apc Deficiency Is Associated with Increased Egfr Activity in the Intestinal Enterocytes and Adenomas of C57BL/6J-Min/+ Mice* , 2004, Journal of Biological Chemistry.

[28]  C. Niehrs,et al.  R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis. , 2004, Developmental cell.

[29]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[30]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[31]  Anton Berns,et al.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.

[32]  J. Monson,et al.  Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. , 2002, Anticancer research.

[33]  R. Fodde The APC gene in colorectal cancer. , 2002, European journal of cancer.

[34]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.

[35]  A. Harris,et al.  Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[37]  U. Scherf,et al.  The hCSE1/CAS protein is phosphorylated by HeLa extracts and MEK-1: MEK-1 phosphorylation may modulate the intracellular localization of CAS. , 1998, Biochemical and biophysical research communications.

[38]  R. Plasterk,et al.  Molecular Reconstruction of Sleeping Beauty , a Tc1-like Transposon from Fish, and Its Transposition in Human Cells , 1997, Cell.

[39]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[40]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. J. Ashley,et al.  The two "hit" and multiple "hit" theories of carcinogenesis. , 1969, British Journal of Cancer.

[42]  M. Kimmel,et al.  Conflict of interest statement. None declared. , 2010 .

[43]  H. Clevers,et al.  EphB/EphrinB receptors and Wnt signaling in colorectal cancer. , 2006, Cancer research.

[44]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[45]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .